Phase 1 dose escalation (DEs) & expansion (DEx) study to evaluate the safety & efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel).
Authors
Darrin M. Beaupre
Emily Liu (ORCID: https://orcid.org/0000-0002-6396-067X)
Phase 1 dose escalation (DEs) & expansion (DEx) study to evaluate the safety & efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel).
Darrin M. Beaupre, Emily Liu, Benjamin Garmezy, Omar Alhalabi et al.
Journal
Journal of Clinical Oncology
Topics
Bladder and Urothelial Cancer Treatments
article
Phase 1 dose escalation (DEs) & expansion (DEx) study to evaluate the safety & efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel).
Darrin M. Beaupre, Emily Liu, Benjamin Garmezy, Omar Alhalabi, Inkeun Park, Valentina Boni, Abhishek Tripathi, Mick O'Quigley, Charlene Mantia, Jordi Rodón, Chang Gon Kim, Melissa L. Johnson, Alexander Z. Wei, Jasgit C. Sachdev, Srikala Devarakonda, Benedito A. Carneiro, Mark N. Stein, Alok K. Tewari, Chang Gon Kim
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(5_suppl)
Institutions
Ulsan College (KR), The University of Texas MD Anderson Cancer Center (US), Yonsei University (KR), Brown University (US), Columbia University Irving Medical Center (US), Severance Hospital (KR), Asan Medical Center (KR), University of Ulsan (KR), Swedish Medical Center (US), Sarah Cannon (US), Ideaya Biosciences (United States) (US), Hospital Universitario Quirónsalud Madrid (ES), City of Hope (US), Dana-Farber Cancer Institute (US), Tennessee Oncology (US), Lifespan (US)